electroCore to Participate in Upcoming Investor Conferences

Rhea-AI Summary

electroCore (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, has announced its participation in two upcoming investor conferences in August 2025.

The company will attend the Needham 10th Annual Virtual MedTech and Diagnostics Conference on August 11-12, 2025, offering one-on-one meetings. Additionally, management will present at the Canaccord Genuity 45th Annual Growth Conference in Boston on August 12 at 3:30 p.m. ET, also providing one-on-one meeting opportunities during the event.

News Market Reaction

+4.27%

1 alert

+4.27% News Effect

+$2M Valuation Impact

$49M Market Cap

0.2x Rel. Volume

On the day this news was published, ECOR gained 4.27%, reflecting a moderate positive market reaction. This price movement added approximately $2M to the company's valuation, bringing the market cap to $49M at that time.

Data tracked by StockTitan Argus on the day of publication.

ROCKAWAY, N.J., July 22, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that management will participate in the following investor conferences.

• Needham 10^th Annual Virtual MedTech and Diagnostics Conference, taking place virtually on Monday, August 11 and Tuesday, August 12, 2025. Management will host will host one-on-one meetings throughout both days.

• Canaccord Genuity 45^th Annual Growth Conference, taking place in Massachusetts on Tuesday, August 12 and Wednesday, August 13, 2025 at the InterContinental in Boston. Management will be presenting on Tuesday, August 12 at 3:30 p.m. ET and will host one-on-one meetings throughout both days.
  

Investors who wish to request a meeting should contact their sales representative at the sponsoring firms or reach out the electroCore Investor Relations at ecor@fnkir.com.

About electroCore, Inc.
electroCore, Inc. is a commercial stage bioelectronic technology company whose mission is to improve health and quality of life through innovative non-invasive bioelectronic technologies. The Company’s two leading prescription products to treat chronic pain syndromes through non-invasive neuromodulation technology are gammaCore non-invasive vagus nerve stimulation (nVNS) and Quell neurostimulator. Additionally, the company commercializes its Truvaga products, handheld, and personal use nVNS products utilizing bioelectronic technologies, to promote general wellness and human performance.

For more information, visit www.electrocore.com.

Contact

ECOR Investor Relations
(973) 302-9253
investors@electrocore.com

FAQ

When is electroCore (ECOR) presenting at the Canaccord Genuity Conference?

electroCore will present at the Canaccord Genuity Conference on Tuesday, August 12, 2025 at 3:30 p.m. ET at the InterContinental in Boston.

How can investors schedule meetings with electroCore management at these conferences?

Investors can request meetings by contacting their sales representative at the sponsoring firms or by reaching out to electroCore Investor Relations at ecor@fnkir.com.

Which investor conferences will electroCore (ECOR) attend in August 2025?

electroCore will participate in the Needham 10th Annual Virtual MedTech and Diagnostics Conference (August 11-12) and the Canaccord Genuity 45th Annual Growth Conference (August 12-13).

Where is the Canaccord Genuity Growth Conference being held?

The Canaccord Genuity 45th Annual Growth Conference is being held at the InterContinental in Boston, Massachusetts.